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Alternate Routes of Administration and Risk for HIV among
Prescription Opioid Abusers
Hilary Surratt, Ph.D., Steven P. Kurtz, PhD, and Theodore J Cicero, PhD
Abstract
Route of administration is an important contributor to the adverse health consequences of
prescription medication abuse. The present study examines characteristics associated with non-
oral routes of administration among a large sample of prescription opioid abusers, and explores
needle related
HIV risk behaviors as well. 791 opioid abusers completed a one-time, structured interview
including complete histories of illicit and prescription drug abuse, and route of drug
administration. The most common method of pill use was oral (91%), followed by intranasal
(53.1%), injection (23.8%), and smoking (14.5%). The youngest prescription opioid abusers, ages
18–24, displayed significantly higher odds of employing alternate route of administration, and also
of re-using nonsterile needles for injection. HIV prevention programming should be developed for
young prescription opioid injectors.
Keywords
prescription opioid abuse; route of administration; HIV
INTRODUCTION
As the well-documented epidemic of prescription drug abuse in the United States continues
to evolve1–3, route of drug administration is emerging as an important contributor to the
adverse health consequences associated with prescription medication abuse.4–6 In this
regard, recent data indicate that non-oral routes of prescription drug ingestion are not
uncommon in samples of high school and college students, rural drug abusers and urban
street drug users7–10, and are associated with greater drug problem severity, including
dependence and overdose.6
Because altered routes of administration provide faster drug delivery and onset, the
reinforcing effects are often intensified 11, thereby increasing the vulnerability to addiction.
Although there are some early indications that young prescription drug abusers seeking
treatment are more likely to use alternate routes of administration and to display greater
problem severity than their older counterparts12, very few studies have systematically
examined route of administration among large, diverse samples of prescription drug abusers.
Moreover, there is general recognition that prescription drug injection increases risk for HIV
and hepatitis infection through the use of non-sterile equipment2, yet studies examining
risky needle use practices among prescription drug injectors are not apparent in the
literature. The present study examines the characteristics associated with alternate routes of
drug administration among large samples of treatment and street-based prescription opioid
abusers in South Florida, and explores the scope of needle risk behaviors among a sub-
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sample of prescription drug injectors to examine risk for HIV and other blood-borne
infections.
METHODS
Participants
Eligible participants were individuals 18 years of age or older who reported abuse of
psychoactive prescription drugs at least 5 times in the past 90 days (or 90 days prior to
treatment entry, where applicable). In addition, participants met criteria for membership in
one of five subpopulations: 1) methadone clients (n = 201) were enrolled in a methadone-
maintenance treatment program; 2) street drug users (n = 106) who reported current illicit
drug use; 3) public treatment clients (n = 147) were enrolled in a publicly funded or
subsidized drug treatment facility for fewer than 45 days prior to interview; 4) private
treatment clients (n = 188) were enrolled in a substance abuse treatment program, paid for
with private insurance personal funds, for fewer than 45 days prior to interview; and, 5) men
who have sex with men (MSM; n = 149) who reported current illicit stimulant use.
Procedures
A variety of purposive sampling strategies were used to locate study participants. Print
media advertisements and the posting or manual distribution of cards and flyers were largely
used to recruit street drug users and MSM. We also used chain-referral sampling to recruit
participants in these subgroups, such that each participant received a $10 cash incentive per
eligible referral that completed an interview, up to a maximum of 5 referrals per participant.
Referrals from methadone clinic and drug treatment center staff served as the primary
recruitment method for methadone maintenance clients and drug treatment enrollees, and
these treatment facilities also provided space for interviews to be conducted. The study was
conducted in the investigators’ research field offices or in treatment centers located in
Broward, Lee, Miami-Dade, and Palm Beach Counties.
All participants were screened for eligibility by trained research staff prior to participation in
a single standardized face-to-face interview. Following informed consent, computer-assisted
face-to-face interviews were conducted in private offices and lasted 1½ to 2 hours.
Participants received a $30 monetary incentive for their participation. All study protocols
and instruments were reviewed and approved by the University of Delaware’s Institutional
Review Board.
Measures
The Global Appraisal of Individual Needs (GAIN)13 was the primary data collection
instrument for the study. The GAIN has eight core sections, including demographics, health
status, mental health, risk behaviors, and substance use, abuse and dependence measures
based on DSM-IV criteria. Questions were added to the GAIN to increase the range of
abused prescription drugs we queried, including hydrocodone, hydromorphone, immediate
(IR) and extended (ER) release oxycodone, morphine, methadone, codeine, as well as
alprazolam, diazepam and clonazepam. We also queried abuse of prescription stimulants,
antidepressants, and antipsychotics. The assessment instrument captured a complete illicit
and non-medical prescription drug history, including number of days using in the past 90
days. Route of administration for prescription medications was assessed through a series of
dichotomous 90-day items querying oral/swallowing, snorting, smoking, injecting, rectal/
vaginal, and other administration. Routes of administration were not mutually exclusive.
HIV testing was beyond the scope of the study, therefore HIV prevalence was captured by
self-report, using the following item: What was the result of your last HIV test (for which
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you received the results)? Past year needle risk behaviors were captured by a series of
dichotomous items querying needle re-use, re-use of non-sterile needles, and sharing needles
with other individuals.
Data Analysis
For the analyses presented here, only participants who reported at least one occasion of
prescription opioid abuse in the past 90 days and those who had complete data on route of
administration items were included (N=1,070). Because route of administration items were
asked jointly for all abused prescription pills, we conducted the analyses in two waves: first,
including all 1,070 prescription opioid abusers, regardless of other prescription medication
abuse; and, second, excluding opioid abusers who also reported any abuse of prescription
stimulants, antidepressants, or antipsychotics (N=791). We were unable to exclude opioid
abusers who also reported benzodiazepine abuse, due to the very high prevalence of
benzodiazepine use in the sample. Comparison of the two analyses revealed no substantive
differences in the findings, therefore, we present only the findings from the smaller, more
focused sample of prescription opioid abusers (N=791).
Data were analyzed using Predictive Analytics Software (PASW, formerly SPSS) version
18. Descriptive statistics were calculated to describe the sample in terms of demographics,
health status, substance use and dependence, and route of prescription drug administration.
Bivariate logistic regression models were developed to predict route of administration by
demographics, sub-population, substance-specific abuse, and DSM IV dependence. Finally,
we computed multivariate logistic regression models to examine patterns of past year risky
needle use among the sub-sample of drug injectors, including age and injection patterns
(prescription vs. illicit drug injection) as predictors.
RESULTS
Sample characteristics are displayed in Table 1. The overall sample was young, with a mean
age of 34.5 years. Given study eligibility criteria, substantial proportions reported illicit drug
use in the 90 days prior to interview. Past 90 day injection of any drug was reported by
29.7% of participants. The prevalence of prescription benzodiazepine abuse in the past 90
days was 78.1%. Among the most commonly abused prescription opioids were immediate
release oxycodone (78.1%), OxyContin® (51.3%), hydrocodone (38.7%), and methadone
(21.2%). Just under 95% of the sample met DSM-IV criteria for substance dependence.
Oral administration was the most common method of pill use (91%), however, substantial
proportions reported alternate routes as well, including intranasal (53.1%), injection
(23.8%), and smoking (14.5%). More than 10% of the sample reported being HIV positive.
Bivariate logistic regression models predicting route of pill administration are displayed in
Table 2. The odds of oral administration were: significantly lower among younger opioid
abusers (ages 18–24, 25–34) compared to older abusers; significantly lower among whites
compared to African Americans; and, significantly lower among all treatment-based
participants compared to street drug users. In terms of substance use, the odds of oral
administration were: significantly higher among powder cocaine users, benzodiazepine
abusers, and codeine abusers compared to non-users of these substances; lower odds of oral
administration were observed among heroin users, OxyContin abusers, and hydromorphone
abusers.
The odds of intranasal administration were: significantly higher among younger opioid
abusers (ages 18–24, 25–34, 35–44) compared to older abusers; significantly higher among
both whites and Latinos compared to African Americans; and, significantly higher among
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all in-treatment participants compared to street drug users. In terms of substance use, the
odds of intranasal pill administration were: significantly higher among heroin users, and
abusers of OxyContin, IR oxycodone, methadone, hydromorphone and hydrocodone; lower
odds of intranasal administration were observed among crack users and codeine abusers.
Past year substance dependence was also associated with increased odds of intranasal pill
use.
Smoking of prescription medications was associated with younger age (18–24), and, the
odds of smoking were significantly higher among public and private treatment participants
compared to street drug users. Methadone clients had lower odds of smoking as a route of
administration compared to street drug users. The odds of smoking were significantly
higher among abusers of OxyContin and IR oxycodone.
The odds of injection of prescription pills were: significantly higher among all younger
opioid abusers (ages 18–24, 25–34, 35–44) compared to older abusers; significantly higher
among both whites and Latinos compared to African Americans; and, significantly higher
among all in-treatment participants compared to street drug users. In terms of substance use,
the odds of injection were: significantly higher among heroin users, and abusers of
OxyContin, IR oxycodone, methadone, hydromorphone and morphine; lower odds of pill
injection were observed among cocaine users and codeine abusers. Past year substance
dependence was associated with increased odds of pill injection. Benzodiazepine use was
not associated with injection or any other non-oral routes of administration.
Multivariate logistic regression models examining past year injection practices are displayed
in Table 3. The youngest age group (18–24) had significantly higher odds of several HIV
risk behaviors, including re-using needles, re-using needles without cleaning them, and
lending needles, compared to their older counterparts. Compared to injectors of illicit drugs,
those also endorsing prescription pill injection were also observed to have significantly
higher odds of re-using unsterile needles.
DISCUSSION
This study is among the first to examine alternative routes of administration in a large and
diverse sample of prescription opioid abusers. The prevalence of non-oral routes of
administration in our sample far exceeds that documented in several studies6–8, but is in line
with estimates from opioid dependent patients in treatment.12 Our findings indicate that
treatment-based individuals had higher odds of abusing prescription opioids through non-
oral routes, as did individuals who met DSM-IVR criteria for past year substance
dependence, regardless of treatment status. These results are consistent with prior research
in suggesting that non-oral routes of drug administration are associated with the
development of more serious drug problems.4
In the present study, we identified race/ethnic differences in the abuse of prescription
medications through alternate routes of administration. Compared to African Americans,
both Hispanic and non-Hispanic white participants had substantially higher odds of snorting
and injecting as routes for medication abuse. Abuse by medication tampering would appear
to represent a more serious degree of opioid involvement among white participants in our
study, which resonates with previous research documenting higher prevalence of
prescription opioid misuse among whites in the general population, college students,
substance abuse treatment clients and illicit drug users. 1, 14–16
Age appeared to play an important role in route of administration as well. The youngest
group of opioid abusers, ages 18–24, uniformly displayed the highest odds of employing
non-traditional routes of administration. This finding accords with prior research indicating
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higher levels of risk taking among younger treatment-based opioid abusers.12 Importantly,
younger individuals are also less knowledgeable about the risks associated with abuse of
prescription opioids by tampering4, and therefore may be especially vulnerable to adverse
health consequences. Our findings demonstrated that the youngest opioid abusers had higher
odds of unsafe needle use behaviors, which presents a substantial risk for exposure to HIV,
hepatitis, and other blood-borne infections.
Notably, our study documented that specific opioids were associated with alternate routes of
administration, particularly snorting and injecting, while others were more typically
associated with oral ingestion. Immediate release oxycodone, OxyContin®, methadone,
morphine, and hydromorphone abuse were each independently associated with higher odds
of injection, while codeine and hydrocodone were not. Our findings add to the existing
literature on substance-specific route of administration.10 Clearly, route of administration is
closely tied to the specific characteristics of the abused medication, including its
pharmacokinetic properties and the presence or absence of additional ingredients, such as
acetaminophen, which can cause unpleasant and harmful effects if taken by injection.
As an additional point, past 90 day heroin use was also found to be strongly associated with
prescription opioid injection among our sample. This appears to represent an additional
piece of evidence in support of the notion that the epidemics of heroin and prescription
opioid abuse are increasingly intertwined. For some time abusers have been observed to
substitute heroin for prescription opioids and vice-versa, based on availability, affordability,
and other considerations, and increasingly it has been noted that prescription opioid abusers
are switching to heroin in areas where heroin is less costly or of higher purity.17, 18 As this
situation continues to evolve, proactive monitoring of early warning systems for adverse
events related to heroin use will be critical.
Our findings should be considered within the context of the study limitations. First, reliance
on self-report data carries the potential for bias in reporting that may have impacted our
prevalence estimates. In addition, measurement of route of prescription drug administration
was somewhat restricted, with items not asked at the drug level. This limited our ability to
examine prescription opioid abuse exclusively. Nevertheless, we documented that
benzodiazepine abuse was not associated with any non-oral routes of administration, and
therefore the route of administration data are attributable to prescription opioids. Lastly,
because this research was conducted in South Florida, an area noted for its high prevalence
of prescription drug abuse and diversion, the findings may not be generalizable to other
locations.
Overall, our findings on route of administration among prescription opioid abusers have
important implications for forward-looking prevention and intervention strategies. First, the
continued development of abuse-deterrent opioid formulations would appear to be
warranted19, particularly for younger individuals at high-risk for opioid abuse through
tampering. From a public health perspective, it is essential that young prescription opioid
injectors be targeted for appropriate HIV and hepatitis education and intervention
programming, as well as harm reduction initiatives. Given their young age and
underrepresentation in populations traditionally considered to be at high-risk for HIV,
increased exposure to injection-related disease prevention measures should be emphasized.
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Table 1
Characteristics of prescription opioid abusers in South Florida (N=791)
N %
Demographics
 Age:
 18–24 176 22.3
 25–34 262 33.1
 35–44 169 21.4
 45+ 184 23.3
 (Mean) 34.5
 Gender (% male): 493 62.3
 Ethnicity:
  Hispanic 125 15.8
  African American/Black 146 18.5
  White 494 62.5
  Other 26 3.3
Subsample:
  Street drug users 106 13.4
  Public treatment clients 147 18.6
  Private treatment clients 188 23.8
  Methadone maintenance clients 201 25.4
  MSM 149 18.8
Substance Use (past 90 days):
 Any drug injection 235 29.7
 Cocaine (powder) 445 56.3
 Crack cocaine 355 44.9
 Heroin 211 26.7
 Rx benzodiazepines 618 78.1
 Rx opioids:
  Oxycodone (excluding OxyContin) 618 78.1
  OxyContin 406 51.3
  Hydrocodone 306 38.7
  Methadone 168 21.2
  Codeine 119 15.0
  Hydromorphone 78 9.9
  Morphine 65 8.2
  Other 81 10.2
Past Year Substance Dependence: 750 94.9
Routes of Prescription Pill Administration:
  Oral 720 91.0
  Snorting 420 53.1
  Injecting 188 23.8
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N %
  Smoking 115 14.5
HIV Status (% Positive)1 77 10.4
1
N=738
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